{"entity":{"id":"nct05195632","kind":"trial","name":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung","aka":["OCEANII"],"tldr":"A phase 2 trial of Encorafenib, Binimetinib in non-small-cell lung cancer and small-cell lung cancer, run by Pierre Fabre Medicament, active and no longer recruiting.","summary":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT05195632 by Pierre Fabre Medicament, with 63 participants enrolled, started 2022-06-02 and due to reach its primary completion in 2024-05-27. Interventions recorded: Encorafenib, Binimetinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05195632","url":"https://clinicaltrials.gov/study/NCT05195632"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","braf-v600e-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["encorafenib","binimetinib"],"companies":["pierre-fabre"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05195632-lung-cancer-2026"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05195632","phase":"2","setting":"Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve","sponsor":"Pierre Fabre Medicament","started":"2022-06-02","startedType":"actual","enrolled":63,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05195632/","neighbours":{"cancer":[{"id":"braf-v600e-nsclc","kind":"cancer","name":"BRAF V600E-mutant non-small-cell lung cancer","route":"/cancers/braf-v600e-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"binimetinib","kind":"drug","name":"Binimetinib","route":"/drugs/binimetinib/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}],"company":[{"id":"pierre-fabre","kind":"company","name":"Pierre Fabre","route":"/companies/pierre-fabre/"}],"paper":[{"id":"paper-nct05195632-lung-cancer-2026","kind":"paper","name":"A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study","route":"/key-papers/paper-nct05195632-lung-cancer-2026/"}]}}